+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Spontaneous in vitro senescence of glioma cells confirmed by an antibody against IDH1R132H



Spontaneous in vitro senescence of glioma cells confirmed by an antibody against IDH1R132H



Anticancer Research 34(6): 2859-2867



We have recently suggested that glioblastoma cells become spontaneously senescent in cell culture conditions. The antibody specific against IDH1(R132H) offers the perfect opportunity to verify this hypothesis. We analyzed the features of senescence in 8 glioma cell cultures showing the IDH1(R132H) mutation based on combination of immunocytochemistry, enzymo-cytochemistry, BrdU incorporation assay and real-time microscopic observation. We report that glioma cells showing the IDH1(R132H) mutation become rapidly and spontaneously senescent in vitro. Senescence was observed in both classical and novel serum-free cell culture conditions. Importantly, the senescent IDH1(R132H)-positive cells showed the expression of stemness marker (SOX2). In vitro senescence appeared to be the main reason of the difficulties in any kind culturing of glioma cells. 3D cell cultures prolonged the survival and in vitro proliferation of neoplastic IDH1(R132H)-positive cells, however, did not enhance the stabilization efficiency. Senescence of glioma cells is spontaneously triggered in vitro, which offers the opportunity of potential new therapeutic strategies based on this phenomenon.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 055889699

Download citation: RISBibTeXText

PMID: 24922649


Related references

OS2.6Identification of IDH1R132H-specific T cell receptors from a humanized mouse model and from glioma patients treated with an IDH1R132H-specific peptide vaccine. Neuro-Oncology 18(Suppl_4): Iv5-Iv6, 2016

A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochemical and Biophysical Research Communications 390(3): 547-551, 2009

O4.08 * Agi5198, An Inhibitor Of Idh1R132H, Protects Idh1R132H Hct116 Cells Against Irradiation. Neuro-Oncology 16(Suppl 2): ii8-ii9, 2014

IDH1R¹³²H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a. Molecular Medicine Reports 12(5): 6695-6701, 2015

P09.04Adoptive T cell therapy for Idh1R132H-mutated low-grade glioma. Neuro-Oncology 18(Suppl_4): iv60, 2016

Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma. Proceedings of the National Academy of Sciences of the United States of America 111(39): 14217-14222, 2014

Os09.9 Identification of Idh1R132H-specific T cell receptors from glioma patients and from Mhc-humanized mice. Neuro-Oncology 19(Suppl_3): iii20, 2017

In vitro evaluation of iodine-125-labeled monoclonal antibody (MAb 425) in human high-grade glioma cells. American Journal of Clinical Oncology 19(6): 601-608, 1996

External beam radiation enhances antibody mediated radiocytotoxicity in human glioma cells in vitro. Anticancer Research 17(3b): 1797-1802, 1997

Simultaneous use of lysosomal inhibitors improves uptake of labeled antibody in human high grade glioma cells in vitro. Journal of Nuclear Medicine 35(5 Suppl. ): 233P, 1994

Detection of human glioma-associated antigen by rat monoclonal antibody raised against syngeneic rat glioma cells. Journal of Neurosurgery 65(4): 495-502, 1986

Mannose-binding protein recognizes glioma cells: in vitro analysis of complement activation on glioma cells via the lectin pathway. Japanese Journal of Cancer Research 86(2): 187-192, 1995

Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo. Oncotarget 6(32): 32930-32943, 2015

TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo. Neuro-Oncology 15(1): 29-40, 2013

Anti-(glioma surface antigen) monoclonal antibody G-22 recognizes overexpressed CD44 in glioma cells. Cancer Immunology Immunotherapy 39(5): 313-317, 1994